To corroborate the role of YAP1/TAZ as an upstream regulator of the MITFlow/AXLhigh melanoma subclass, and as a driver of resistance to MAPKis across melanoma cell lines and patient tumors, we scored for YAP1/TAZ activity using an established pancancer YAP1/TAZ target gene signature (Fig. 2a and Supplementary Table 2) [28]. This evidence concerns the gene YAP1 and melanoma.